Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AssigneeGenentech, Inc.
InventorMARK C. BENYUNES
Life of this patent
Estimating the term…
Abstract
The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.
Claims25
A method of treating an autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor, comprising administering to the mammal a therapeutically effective amount of an antagonist which binds to a B cell surface marker.
A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNFα-inhibitor, comprising administering to the patient a therapeutically effective amount of an antibody that binds to CD20.
A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNFα-inhibitor, comprising administering to the patient two intravenous doses of 1000 mg of an antibody that binds to CD20 .
A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNFα-inhibitor, comprising administering to the patient an antibody which binds to CD20 in an amount that is effective to provide an ACR50 response at week 24, ACR70 response at week 24, or no erosive progression at weeks 24 and beyond.
Dependencies are inferred from the claim text.